Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Cystic Fibrosis Foundation evidence-based guideline for the management of CRMS/CFSPID
Green DM, Lahiri T, Raraigh KS, Ruiz F, Spano J, Antos N, Bonitz L, Christon L, Gregoire-Bottex M, Hale JE, Langfelder-Schwind E, Perez ALP, Maguiness K, Massie J, McElroy-Barker E, McGarry ME, Mercier A, Munck A, Oliver KE, Self S, Singh K, Smiley S, Snodgrass S, Tluczek A, Tuley P, Lomas P, Wong E, Hempstead SE, Faro A, Ren CL [Cystic Fibrosis Foundation]
Pediatrics May;153(5):e2023064657
practice guideline

A multidisciplinary committee developed evidence-based guidelines for the man- agement of cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen-positive, inconclusive diagnosis (CRMS/ CFSPID). A total of 24 patient, intervention, comparison, and outcome questions were generated based on surveys sent to people with CRMS/CFSPID and clinicians caring for these individuals, previous recommendations, and expert com- mittee input. Four a priori working groups (genetic testing, monitoring, treatment, and psychosocial/communication issues) were used to provide structure to the committee. A systematic review of the evidence was con- ducted, and found numerous case series and cohort studies, but no randomized clinical trials. A total of 30 recommendations were graded using the US Preventive Services Task Force methodology. Recommendations that received $80% consensus among the entire committee were approved. The resulting recommendations were of moderate to low certainty for the ma- jority of the statements because of the low quality of the evidence. High- lights of the recommendations include thorough evaluation with genetic sequencing, deletion/duplication analysis if <2 disease-causing variants were noted in newborn screening; repeat sweat testing until at least age 8 but limiting further laboratory testing, including microbiology, radiology, and pulmonary function testing; minimal use of medications, which when suggested, should lead to shared decision-making with families; and providing communication with emphasis on social determinants of health and shared decision-making to minimize barriers which may affect processing and understanding of this complex designation. Future research will be needed regarding medication use, antibiotic therapy, and the use of chest imaging for monitoring the devel- opment of lung disease. https://publications.aap.org/pediatrics/article/153/5/e2023064657/197079/Cystic-Fibrosis-Foundation-Evidence-Based?autologincheck=redirected
Reproduced with permission from Pediatrics. Copyright by the American Academy of Pediatrics.

Full text (sometimes free) may be available at these link(s):      help